Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Leukotriene antagonist and antihistaminics composition

A technology of leukotriene antagonists and antihistamines, applied in the directions of drug combinations, anti-inflammatory agents, active ingredients of heterocyclic compounds, etc.

Inactive Publication Date: 2010-07-14
北京华禧联合科技发展有限公司
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the patent of the combination of montelukast sodium and olopatadine hydrochloride

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1: Montelukast Olopatadine Compound Capsules

[0015] prescription:

[0016] Montelukast 4g

[0017] Olopatadine 2.5g

[0018] Lactose 70

[0019] Starch 30

[0020] Sodium carboxymethyl starch 10g

[0021] Magnesium Stearate 1g

[0022] 10% starch slurry appropriate amount

[0023]

[0024] A total of 1000 capsules were made

[0025] Preparation:

[0026] (1) All raw and auxiliary materials are pulverized through a 100-mesh sieve for subsequent use;

[0027] (2) Weigh lactose, starch, sodium carboxymethyl starch in the prescribed amount and mix uniformly to obtain material I, take montelukast and olopatadine in the prescribed amount, add the same amount to material I, and mix uniformly to obtain material II ;

[0028] (3) The material II is made into a suitable soft material with 10% starch slurry in an appropriate amount, passed through a 20-mesh sieve to granulate, ventilated and dried at 50° C., controlling the mois...

Embodiment 2

[0030] Embodiment 2: Montelukast Olopatadine Compound Tablet

[0031] prescription:

[0032] Montelukast 5g

[0033] Olopatadine 5g

[0034] Microcrystalline Cellulose 40g

[0035] Hydroxypropyl Cellulose 10

[0036] Mannitol 90g

[0037] Polyethylene glycol 6000 10

[0038]

[0039] A total of 1000 pieces were made

[0040] Preparation:

[0041] (1) All the raw and auxiliary materials are pulverized and passed through an 80-mesh sieve, and set aside;

[0042] (2) Microcrystalline Cellulose, hydroxypropyl cellulose, mannitol, and polyethylene glycol 6000 that take prescription quantity mix homogeneously, obtain material I, get the montelukast and olopatadine of prescription quantity, equal amount Add material I and mix well to obtain material II;

[0043] (3) The material II is directly compressed into tablets under an appropriate pressure, and then packaged.

Embodiment 3

[0044] Embodiment 3: Montelukast Olopatadine Compound Capsules

[0045] prescription:

[0046] Montelukast 10g

[0047] Olopatadine 10g

[0048] Cross-linked polyvinylpyrrolidone 35g

[0049] Lactose 85

[0050] Talc powder 5g

[0051] 10% PVPk30 appropriate amount

[0052]

[0053] A total of 1000 capsules were made

[0054] Preparation:

[0055] (1) All raw and auxiliary materials are pulverized through a 100-mesh sieve for subsequent use;

[0056] (2) Montelukast, olopatadine, cross-linked polyvinylpyrrolidone and lactose are weighed and mixed uniformly to obtain material I;

[0057] (3) Material I is made into a suitable soft material with 10% PVPk30 in an appropriate amount, passed through a 20-mesh sieve to granulate, ventilated and dried at 50° C., controlling moisture content to 1-2%, and granulated with an 18-mesh sieve.

[0058] (4) Add talcum powder to the dry granules, mix evenly, fill capsules, and pack.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating asthma, allergic reaction and inflammation. The composition comprises a leukotriene antagonist, antihistaminics and medicinal carriers, wherein the leukotriene antagonist is Montelukast and salts thereof, and the antihistaminics is olopatadine hydrochloride and salts thereof. The composition is suitable for preventing and long-term treating of asthma for children and adults, and can treat asthma patients sensitive to aspirin, prevent bronchoconstriction induced by movement, treat pruritus concomitant with allergic rhinitis, urticaria and skin diseases, and the like. The composition has better curative effect compared with that the two medicines are used independently.

Description

technical field [0001] The present invention relates to a composition of leukotriene antagonist and antihistamine, specifically the composition of montelukast sodium and olopatadine hydrochloride. Background technique [0002] Bronchial asthma is a chronic inflammatory disease of the respiratory tract characterized by hyperresponsiveness of the respiratory tract. Its pathogenesis is complex and involves many inflammatory response mediators, cytokines, chemical factors and related cellular components. Among them, leukotrienes (LTs) are the main inflammatory response mediators in the development of asthma, and are currently the most promising way to target a single substance, which can not only promote the accumulation of inflammatory response cells in the respiratory tract, but also increase vascular permeability It can also cause the contraction of airway smooth muscle, promote the proliferation of airway structural cells, and thus participate in the occurrence of airway inf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/47A61K31/335A61P29/00A61P37/08A61P11/06
Inventor 胡淑娟谢晓东王建航张志芳
Owner 北京华禧联合科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com